Glaukos (GKOS) News Today $160.50 -0.72 (-0.45%) Closing price 03:59 PM EasternExtended Trading$162.64 +2.14 (+1.33%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period $1000 Invested In Glaukos 5 Years Ago Would Be Worth This Much TodayJanuary 24 at 11:22 AM | benzinga.comZweig DiMenna Associates LLC Takes $8.80 Million Position in Glaukos Co. (NYSE:GKOS)Zweig DiMenna Associates LLC acquired a new position in shares of Glaukos Co. (NYSE:GKOS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 58,665 shares of the medical instruments supplier'sJanuary 24 at 9:49 AM | marketbeat.comGlaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20January 23 at 9:04 AM | finance.yahoo.comGlaukos Co. (NYSE:GKOS) Shares Sold by Riverbridge Partners LLCRiverbridge Partners LLC cut its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 34.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 312,931 shares of the medical instruments supplier'sJanuary 23 at 7:46 AM | marketbeat.comGlaukos Co. (NYSE:GKOS) Receives $147.75 Average PT from BrokeragesJanuary 22 at 2:11 AM | americanbankingnews.comGlaukos (NYSE:GKOS) Reaches New 12-Month High - What's Next?Glaukos (NYSE:GKOS) Hits New 1-Year High - Here's What HappenedJanuary 21 at 3:54 PM | marketbeat.comGlaukos stock soars to all-time high, reaches $161.17January 21 at 2:47 PM | msn.comAssenagon Asset Management S.A. Decreases Stock Position in Glaukos Co. (NYSE:GKOS)Assenagon Asset Management S.A. trimmed its position in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 24.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 56,984 shares of the medical instruments supplier's stock after selling 18,814January 20, 2025 | marketbeat.comGlaukos Co. (NYSE:GKOS) Short Interest UpdateGlaukos Co. (NYSE:GKOS - Get Free Report) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 3,040,000 shares, a growth of 18.3% from the December 15th total of 2,570,000 shares. Based on an average daily volume of 567,300 shares, the days-to-cover ratio is currently 5.4 days.January 19, 2025 | marketbeat.comOak Ridge Investments LLC Acquires Shares of 11,150 Glaukos Co. (NYSE:GKOS)Oak Ridge Investments LLC acquired a new stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 11,150 shares of the medical instruments supplier's stock, valued atJanuary 19, 2025 | marketbeat.comGlaukos Co. (NYSE:GKOS) Given Average Rating of "Moderate Buy" by AnalystsShares of Glaukos Co. (NYSE:GKOS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the thirteen brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued aJanuary 19, 2025 | marketbeat.comPositive Outlook for Glaukos Driven by Encouraging iDose Data and Promising Pipeline DevelopmentsJanuary 16, 2025 | markets.businessinsider.comWells Fargo Sticks to Their Buy Rating for Glaukos (GKOS)January 16, 2025 | markets.businessinsider.comGlaukos Corporation (NYSE:GKOS) Unveils Investor Presentation in 8-K FilingAliso Viejo, California - Glaukos Corporation, a Delaware-based company specializing in eye care innovations, recently filed an 8-K report with the SEC, disclosing its intent January 16, 2025 | americanbankingnews.comGlaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical PlatformJanuary 14, 2025 | businesswire.comHarbor Capital Advisors Inc. Invests $3.68 Million in Glaukos Co. (NYSE:GKOS)Harbor Capital Advisors Inc. acquired a new stake in Glaukos Co. (NYSE:GKOS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 24,539 shares of the medical instruments supplier's stock, valued at approximately $3,679,000. Several oJanuary 11, 2025 | marketbeat.comGlaukos (NYSE:GKOS) Hits New 1-Year High - Still a Buy?Glaukos (NYSE:GKOS) Hits New 12-Month High - Here's What HappenedJanuary 6, 2025 | marketbeat.comBTIG Sticks to Its Buy Rating for Glaukos (GKOS)January 4, 2025 | markets.businessinsider.comGlaukos price target raised to $157 from $149 at BTIGJanuary 4, 2025 | finance.yahoo.comWhat 11 Analyst Ratings Have To Say About GlaukosJanuary 1, 2025 | benzinga.comGlaukos price target raised to $175 from $153 at StifelDecember 31, 2024 | markets.businessinsider.comGlaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For TuesdayDecember 31, 2024 | benzinga.comGlaukos (NYSE:GKOS) Price Target Raised to $175.00Stifel Nicolaus raised their price target on Glaukos from $153.00 to $175.00 and gave the stock a "buy" rating in a research report on Tuesday.December 31, 2024 | marketbeat.comFranklin Resources Inc. Has $2.03 Million Holdings in Glaukos Co. (NYSE:GKOS)Franklin Resources Inc. increased its position in Glaukos Co. (NYSE:GKOS - Free Report) by 80.1% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 15,621 shares of the medical instruments supplier's stock after purchasing an additional 6,948 shares during thDecember 27, 2024 | marketbeat.comGlaukos (NYSE:GKOS) Reaches New 1-Year High - Time to Buy?Glaukos (NYSE:GKOS) Reaches New 1-Year High - Should You Buy?December 25, 2024 | marketbeat.comGlaukos Co. (NYSE:GKOS) Given Consensus Rating of "Moderate Buy" by BrokeragesGlaukos Co. (NYSE:GKOS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the thirteen research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, ten have given aDecember 25, 2024 | marketbeat.comGlaukos Co. (NYSE:GKOS) Shares Sold by Principal Financial Group Inc.Principal Financial Group Inc. reduced its position in Glaukos Co. (NYSE:GKOS - Free Report) by 3.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 288,505 shares of the medical instruments supplier's stocDecember 24, 2024 | marketbeat.comJoseph E. Gilliam Sells 3,328 Shares of Glaukos Co. (NYSE:GKOS) StockDecember 24, 2024 | insidertrades.comGlaukos submits NDA to U.S. FDA for Epioxa to treat keratoconusDecember 24, 2024 | markets.businessinsider.comJoseph E. Gilliam Sells 3,328 Shares of Glaukos Co. (NYSE:GKOS) StockGlaukos Co. (NYSE:GKOS - Get Free Report) COO Joseph E. Gilliam sold 3,328 shares of the company's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $149.85, for a total value of $498,700.80. Following the sale, the chief operating officer now owns 102,169 shares of the company's stock, valued at approximately $15,310,024.65. This represents a 3.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.December 23, 2024 | marketbeat.comGlaukos Co. (NYSE:GKOS) Director Gilbert H. Kliman Sells 10,000 SharesGlaukos Co. (NYSE:GKOS - Get Free Report) Director Gilbert H. Kliman sold 10,000 shares of the firm's stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $150.28, for a total value of $1,502,800.00. Following the transaction, the director now owns 32,336 shares in the company, valued at approximately $4,859,454.08. This trade represents a 23.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.December 23, 2024 | marketbeat.comGlaukos Submits New Drug Application to U.S. FDA for Epioxa™December 23, 2024 | finance.yahoo.comThe three-year returns have been stellar for Glaukos (NYSE:GKOS) shareholders despite underlying losses increasingDecember 21, 2024 | au.finance.yahoo.comGlaukos: Still Bullish, But Embedded Expectations Are Now HighDecember 21, 2024 | seekingalpha.comGlaukos (GKOS) Receives a Buy from Stifel NicolausDecember 20, 2024 | markets.businessinsider.comGlaukos (NYSE:GKOS) Hits New 1-Year High Following Analyst UpgradeGlaukos (NYSE:GKOS) Reaches New 12-Month High on Analyst UpgradeDecember 19, 2024 | marketbeat.comGlaukos price target raised to $185 from $152 at TruistDecember 18, 2024 | markets.businessinsider.comTruist Financial Issues Positive Forecast for Glaukos (NYSE:GKOS) Stock PriceTruist Financial boosted their price objective on Glaukos from $152.00 to $185.00 and gave the stock a "buy" rating in a research note on Wednesday.December 18, 2024 | marketbeat.comTidal Investments LLC Purchases 6,767 Shares of Glaukos Co. (NYSE:GKOS)Tidal Investments LLC boosted its position in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 83.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,908 shares of the medical instrumentsDecember 17, 2024 | marketbeat.comGeode Capital Management LLC Acquires 66,134 Shares of Glaukos Co. (NYSE:GKOS)Geode Capital Management LLC grew its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 6.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,172,016 shares of the medical instruments supplier's stock aDecember 17, 2024 | marketbeat.comGlaukos Co. (NYSE:GKOS) Shares Purchased by Barclays PLCBarclays PLC grew its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 394.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 89,699 shares of the medical instruments supplier'December 17, 2024 | marketbeat.comGlaukos Co. (NYSE:GKOS) Short Interest Down 5.3% in NovemberGlaukos Co. (NYSE:GKOS - Get Free Report) was the target of a large decrease in short interest in November. As of November 30th, there was short interest totalling 2,660,000 shares, a decrease of 5.3% from the November 15th total of 2,810,000 shares. Based on an average daily volume of 526,000 shares, the short-interest ratio is presently 5.1 days.December 17, 2024 | marketbeat.comTeachers Retirement System of The State of Kentucky Grows Position in Glaukos Co. (NYSE:GKOS)Teachers Retirement System of The State of Kentucky increased its position in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 84.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 28,470 shares of the medical instrumentsDecember 14, 2024 | marketbeat.comGilbert H. Kliman Sells 2,000 Shares of Glaukos Co. (NYSE:GKOS) StockGlaukos Co. (NYSE:GKOS - Get Free Report) Director Gilbert H. Kliman sold 2,000 shares of the business's stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total value of $288,020.00. Following the completion of the sale, the director now owns 32,336 shares of the company's stock, valued at $4,656,707.36. This trade represents a 5.82 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.December 13, 2024 | marketbeat.comY Intercept Hong Kong Ltd Takes $1.01 Million Position in Glaukos Co. (NYSE:GKOS)Y Intercept Hong Kong Ltd bought a new position in Glaukos Co. (NYSE:GKOS - Free Report) in the third quarter, according to its most recent filing with the SEC. The firm bought 7,724 shares of the medical instruments supplier's stock, valued at approximately $1,006,000. Several other large investorDecember 13, 2024 | marketbeat.comGlaukos (GKOS) Receives a Buy from J.P. MorganDecember 12, 2024 | markets.businessinsider.comCitigroup Upgrades Glaukos (GKOS)December 12, 2024 | msn.comState Street Corp Raises Stock Holdings in Glaukos Co. (NYSE:GKOS)State Street Corp raised its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 5.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,954,449 shares of the medical instruments supplier's stock after purchasing an addiDecember 12, 2024 | marketbeat.comWells Fargo Sticks to Its Buy Rating for Glaukos (GKOS)December 11, 2024 | markets.businessinsider.comGlaukos (NYSE:GKOS) Rating Increased to Buy at CitigroupCitigroup upgraded shares of Glaukos from a "neutral" rating to a "buy" rating and raised their price objective for the company from $132.00 to $162.00 in a research note on Wednesday.December 11, 2024 | marketbeat.com Get Glaukos News Delivered to You Automatically Sign up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter. Email Address GKOS Media Mentions By Week GKOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GKOS News Sentiment▼0.970.61▲Average Medical News Sentiment GKOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GKOS Articles This Week▼117▲GKOS Articles Average Week Get Glaukos News Delivered to You Automatically Sign up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PHG News ZBH News SOLV News SNN News PEN News BLCO News INSP News NARI News PRCT News NVST News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:GKOS) was last updated on 1/24/2025 by MarketBeat.com Staff From Our PartnersDo this Before Elon’s Reveal on January 29thElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Manhattan Project Now UnderwayJust as I predicted, President Trump announced his #1 move during his first 100 days... His allies are call...Banyan Hill Publishing | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Glaukos Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Glaukos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
